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Abstract
Background: Anticoagulants reduce the risk of venous thromboembolism (VTE) after total joint replacement. However,
concern remains that pharmacologic VTE prophylaxis can lead to bleeding, which may impact on postoperative
complications such as infections and reoperations.
Methods and Findings: From the Global Orthopedic Registry (GLORY), we reviewed 3,755 patients in US who elected for
primary total hip or knee arthroplasty, received either warfarin or low molecular weight heparin (LMWH) as VTE
prophylactics, and had up-to-90-day follow-up after discharge. We compared incidence rates of VTE, infections and other
complications between LMWH and warfarin groups, and used multivariate analyses with propensity score weighting to
generate the odds ratio (OR). Patients receiving LMWH tended to be older and higher in the American Society of
Anesthesiologists grade scores. In contrast, warfarin was used more frequently for hip arthroplasty with longer duration
among patients with more pre-existing comorbidity (all P,0.02). A weight variable was created with propensity score to
account for differences in covariate distributions. Propensity score-weighted analyses showed no differences in VTE
complications. However, compared to warfarin, LMWH was associated with significantly higher rates of bleeding (6.2% vs.
2.1%; OR= 3.82, 95% confidence interval [CI], 2.64 to 5.52), blood transfusion (29.4% vs. 22.0%; OR= 1.75, 95% CI, 1.51 to
2.04), reoperations (2.4% vs. 1.3%; OR= 1.77, 95% CI, 1.07 to 2.93) and infections (1.6% vs. 0.6%; OR= 2.79, 95% CI, 1.42 to
5.45). Similar results were obtained from compliant uses of warfarin (26%) and LMWH (62%) according to clinical guidelines.
While surgical site infections were mostly superficial, current study was underpowered to compare incidence rates of deep
infections (,1.0%).
Conclusions: Surgical site infections and reoperations in 3 months following primary total joint arthroplasty may be
associated with anticoagulant use that exhibited higher bleeding risk. Long-term complications and deep wound infections
remain to be studied.
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Introduction
It is well established that anticoagulant prophylaxis reduces
symptomatic deep vein thrombosis (DVT) or venous thromboem-
bolism (VTE) following elective total joint arthroplasty. Numerous
chemoprophylactic regimens have been incorporated into evi-
dence based guidelines [1,2]. However, there remains an intrinsic
balance between preventing VTE through anticoagulation and
avoiding excess bleeding due to anticoagulant use. Surgeons have
in the past expressed great concern that postoperative bleeding
could lead to surgical site complications [3]. Surgical site
complications such as infections represent potentially serious
complications [4] that delay patient recovery and increase the
burden to the healthcare system [5] and remain as one of the main
reasons for revision surgery [6]. Excess bleeding associated with
prophylactic use of anticoagulants could contribute to complica-
tions such as oozing [7], hematoma formation and wound
drainage [8]. Although previous single site studies suggested an
association between anticoagulant prophylaxis and postoperative
infections [9–11], there have been no multi-center studies that
addressed the associations between VTE prophylaxis and surgical
site infections [12].
In this study, we analyzed data from the Global Orthopedic
Registry (GLORY), an international registry that collected data
from surgeons who used different VTE prophylactics for patients
undergoing primary elective total hip and knee arthroplasty [13].
We compared the incidence rates of postoperative complications
associated with two most common prophylactic treatment
regimens in the United States, i.e., low molecular weight heparin
(LMWH) and warfarin, which have been shown to differ in their
risk profiles for bleeding [14].
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Methods
Ethics Statement
The study was exempted by the institutional review boards at
the National Institutes of Health and no informed consent was
deemed necessary for this study, although individual consent had
been obtained from patients who participated in GLORY.
Data Sources and Study Population
The study was initiated following the completion of GLORY
and publications of its findings [15–18]. The GLORY registry was
designed to monitor a wide range of practices, complications and
outcomes. Briefly, 156 orthopedic surgeons from 100 hospitals in
13 countries prospectively collected information on standard case
report forms from the first 10 cases of elective hip or knee
arthroplasty patients each month from 2001 to 2004. Data were
centrally managed about their demographics, treatment regimen
and monitoring of complications during in-hospital stays, 3-month
and 12-month follow-ups. We only included patients with up to 3
months of follow up for this analysis, due to excessive lost-to-
follow-up at 12-month follow-up. In addition, we chose the US
region because LMWH and warfarin were utilized as two of the
most prevalent forms of pharmacologic prophylaxes in US
(Figure 1), whereas most patients from Europe received LMWH.
We did not include the naı¨ve control group who did not have any
record for prophylaxis (n = 30), or those who only got mechanical
prophylaxis (n = 159).
Outcomes
The primary outcomes were clinician-reported symptomatic
VTE during hospitalization or within 3 months after hospital
discharge. Surgical site infections or reoperations were reported
respectively as wound infections or surgical procedures involving
incision, within 90-day period following surgery. VTE included
symptomatic deep vein thrombosis (confirmed by venography,
duplex ultrasound, or other objective method of diagnosis) or
symptomatic pulmonary embolism (confirmed by lung scan, CT,
pulmonary angiogram, or other objective method of diagnosis).
Other outcomes included length of hospital stay for the primary
procedure, bleeding, blood transfusion, the volume of blood
transfused and miscellaneous complications. For bleeding, we
included those cases with two or more units of blood transfused
during surgery, plus bleeding-related complications such as
reoperation due to bleeding, delayed hospital discharge due to
bleeding, hematoma requiring evacuation, epidural hematoma,
gastrointestinal bleeding, GI bleed, and hemorrhage requiring
hospital readmission.
Statistical Analysis
Baseline characteristics of the patients were compared between
treatment groups with the Pearson chi-square test. As most of the
Figure 1. Study cohort. Note that 84.7% of patients who received warfarin and 93.3% of those with LMWH also received elastic stockings and/or
intermittent pneumatic compression devices. There were 30 patients of US patients who did not have record for prophylaxis, and 159 of them
receiving mechanical prophylaxis only. GLORY: Global Orthopedic Registry. LMWH, low molecular weight heparin.
doi:10.1371/journal.pone.0091755.g001
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outcomes were binary (yes/no), we used multivariate logistic
regressions with choice of prophylaxis as the main covariate in
addition to the following variables: age, sex, body-mass index
(BMI), year of surgery, type of surgery (hip/knee), antibiotic use,
length of surgery, co-morbid conditions, and the American society
of Anesthesiologists (ASA) score.
Since these prophylaxis groups were not randomly assigned but
different with respect to patients’ demographic and clinical
characteristics, we balanced the groups with propensity score
adjustment. Propensity scoring is a well-established statistical
method that controls for selection bias in observational studies by
using a weighted score to balance the two cohorts [19–21].
Propensity scores were generated using multivariate logistic
regression to calculate probability of receiving warfarin vs
LMWH, based on patient characteristics including age, sex,
BMI, year of surgery, type of surgery, antibiotic use, length of
surgery, co-morbid conditions, and ASA score.
As is common in multicenter registry studies, a number of
patients had missing values for variables such as weight or ASA
score. Missing values would have substantially reduced our sample
size. Thus prior to the propensity score weighting, multiple
imputation was used to impute variables with missing values
[22,23]. Multiple imputation was implemented not only to reduce
estimate bias associated with complete case analysis, but also to
Table 1. Baseline Characteristics of the US Patients from the Global Orthopedic Registry (GLORY, N= 3,755).
Unadjusted Adjusted with Propensity Score Weighting
LMWH (N=1,561) Warfarin (N=2,194) P Value LMWH (N=1,561) Warfarin (N=2,194) P Value
Year of surgery 0.006 0.99
2001 12.9 14.0 13.8 13.8
2002 37.9 33.4 35.2 35.1
2003 32.1 36.8 34.4 34.7
2004 17.1 15.8 16.6 16.4
Age in years 0.002 0.99
18–54 13.7 18.2 16.3 16.2
55–64 23.9 21.8 22.8 22.8
65–74 34.3 33.9 33.6 33.9
75+ 28.1 26.1 27.3 27.1
Joint ,0.001 0.82
Hip 31.1 45.9 40.4 40.0
Knee 68.9 54.2 59.6 60.0
ASA scores 0.002 0.86
No chronic conditions 12.7 16.1 15.6 15.0
Mild chronic conditions 57.5 58.3 57.9 58.2
Severe or moribound 29.8 25.6 26.4 26.8
Sex 0.67 0.89
Male 41.1 41.8 41.7 41.5
Female 58.9 58.2 58.3 58.5
Body mass index (BMI) 0.41 0.99
Under Weight 0.5 0.6 0.6 0.6
Norm Weight 15.2 16.2 16.3 16.3
Over Weight 33.7 35.6 34.5 34.6
Obese 50.6 47.6 48.6 48.5
Length of surgery ,0.001 0.86
,2 Hours 91.6 81.4 86.7 87.1
2–4 Hours 8.3 18.3 13.1 12.8
.4 Hours{ 0.1 0.3 0.2 0.1
Prior conditions ,0.001 0.75
No 86.4 81.0 82.7 83.2
Yes 13.6 19.0 17.3 16.8
Antibiotics use 0.004 0.87
None 0.5 1.6 1.1 1.1
Prophylaxis only 97.9 96.4 96.6 96.9
Additional Indication 1.7 2.0 2.3 2.0
ASA, American society of Anesthesiologists; LMWH, low molecular weight heparin.
doi:10.1371/journal.pone.0091755.t001
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improve the performance of propensity scores. To implement the
multiple imputation, we used IVEware version 2.0 (Ann Arbor,
MI) to generate 5 datasets with the same number of observations
as the original dataset [24]. Propensity scores were generated for
each dataset and effect size was estimated per dataset. To
summarize the data, Rubin’s rule was used to generate the final
statistics [22,25]. We performed additional analyses by setting
missing to a separate category in the original dataset and results
were similar. It should be noted that missing values were imputed
only for covariates, not for outcomes or exposure variables.
All significance tests were conducted at two-sided level of 0.05.
Since testing for association between prophylaxes and numerous
complications was planned a priori, we did not adjust a level for
multiple comparisons. Due to limited sample size, we only
conducted significance tests for those comparison groups with
minimal difference of 20% and one of rates at least over 1%. The
statistical analysis was conducted using SAS 9.3 (SAS Institute Inc,
Cary, North Carolina).
Results
Cohort Characteristics
From the US study population, 1,508 and 2,247 patients
underwent hip and knee arthroplasty, respectively. Among these
patients, 2,194 initiated prophylaxis with warfarin whereas 1,561
received prophylaxis with LMWH. For prophylaxis, warfarin was
taken either preoperatively (40.0%) or within 24 hours postoper-
atively (60.0%), whereas LMWH was administered in 81% of
cases from 7 to 36 hours following surgery. It should be noted that
85% of patients who received warfarin and 93% of those with
LMWH also received elastic stockings and/or intermittent
pneumatic compression devices.
Table 1 shows selected baseline characteristics of the study
population. Significant differences were observed among all the
variables related to the patient demographic and clinical
characteristics except for sex and BMI. Patients treated with
LMWH tended to be older and higher in the American Society of
Anesthesiologists grade scores. In contrast, warfarin was used
among patients with more pre-existing conditions (all P,0.02). We
used propensity score weighting to control for the differences in
covariate distributions as shown in Table 1.
Bivariate and Multivariate Analyses
Since the test results were similar between bivariate and
multivariate analyses, we only show the P values following
multivariate analyses with propensity-score weighting. As shown
in Table 2, the lengths of hospital stay were not significantly
different between two groups (P = 0.40) and the overall risks of
general medical complications were similar between LMWH and
warfarin groups (LMWH vs. warfarin: 3.1 vs 2.6%; OR, 1.41;
95% CI, 0.96 to 2.07). Similarly, the risks of symptomatic VTE
were comparable between the two groups (LMWH vs. warfarin:
1.5 vs 0.9%; OR, 1.72; 95% CI, 0.93 to 3.17) (Table 2).
However, compared to those with warfarin, patients treated
with LMWH were more likely to receive blood transfusion
(LMWH vs. warfarin: 29.4 vs 22.0%; OR, 1.75; 95% CI, 1.51 to
2.04) and had higher volume of blood transfusion (LMWH vs.
warfarin: mean 6 SD: 6146371 vs 5246227). They also had
significantly higher risks for bleeding (LMWH vs. warfarin: 6.2 vs
2.1%; OR, 3.82; 95% CI, 2.64 to 5.52) and surgical site infections
(LMWH vs. warfarin: 1.6 vs 0.6%; OR, 2.79; 95% CI, 1.42 to
5.45). Most of the surgical site infections in the LMWH group
were deemed by the reporting surgeon as superficial (LMWH vs.
warfarin: 1.3 vs 0.4%; OR, 3.47; 95% CI, 1.53 to 7.84). No
significance tests were conducted in the rates of deep infections,
per pre-specified testing rule.
In addition, patients treated with LMWH had higher rates of
reoperation compared to those with warfarin (LMWH vs.
warfarin: 2.3 vs 1.3%; OR, 1.77; 95% CI, 1.07 to 2.93).
Reoperations due to infection were slightly higher in the LMWH
group, but no significance test was done (LMWH vs. warfarin: 0.7
vs 0.5%). 21 out of 49 infections were treated with reoperations,
wherein 9 out of 11 deep infections and 12 out of 38 superficial
infections did.
Subgroup Analyses
Using 2001 edition of American College of Chest Physicians
(ACCP) guidelines for VTE prophylaxis, we limited the sample to
patients who were compliant with the contemporaneous ACCP
guidelines in terms of type, duration, starting time and dose of
prophylactics. Based on whether a target international normali-
zation ratio (INR) of 2.0–3.0 was achieved, only 26.2% of warfarin
use was compliant (n = 575). In comparison, 62.3% use of LMWH
was compliant based on the dosage and time window of
commencement (at regular dosage either within 12 hours before
the surgery, or 12–24 hours after surgery, or at half the usual dose
within 4–6 hours after surgery and continuing with the usual dose
on the following day, n = 973). As shown in Table 3, the incidence
rates of infections within 3 months after discharge for LMWH sub
group was 2.0%, compared to 0.4% in the warfarin subgroup
(OR, 5.07; 95% CI, 1.30 to 19.77; P = 0.02). The risk of bleeding
was significantly higher in LMWH group (OR, 3.98; 95% CI, 2.10
to 7.56; P,0.01) as was that of reoperation (OR, 3.42; 95% CI,
1.26 to 9.29; P = 0.02).
Discussion
In this registry based analysis, we observed that compared to
warfarin, LMWH was associated with higher incidences of blood
transfusions and bleeding. Concurrently, we also observed that
LMWH was associated with higher rates of wound infections and
reoperations. This is consistent with our hypothesis that patients
treated with different anticoagulants with varying bleeding risk,
would have significant difference in infections or other complica-
tions. However, the clinical significance of our observation is not
clear as the majority of infections were deemed superficial with
nearly half treated without reoperation. The limited number of
bleeding episodes and deep infections prevented us from studying
the involvement of bleeding and clinical significance of infections.
Several studies have noted that excessive anticoagulation was
associated with prolonged wound drainage that is conducive for
the development of infection. There seems to be a clinical balance
between providing anticoagulation that prevents deep vein
thrombosis and allowing the surgical wound to heal. Hematoma
formation can result in wound drainage that can predispose
patients towards infection [10,11,26–29]. Thus, the results of our
study are expected based on these observations.
Though the GLORY registry is large and national in scope, we
found two difficulties in analyzing the data. First, we found that the
patients treated with LWMH formed a different cohort than
warfarin patients. We used propensity score matching to balance
the respective cohorts such that comparison could be allowed.
Second, we found that a number of variables (such as duration of
surgery) were missing from the registry. Restricting the analysis to
only those cases with complete data would have degraded the
sample size considerably and biased the results, so multiple
imputation was used to address missing data [19–21]. We
compared the distributions of imputed variables such as length
Thromboprophylaxis and Postoperative Complications
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of surgery among US surgeons with those of surgeons from Europe
where data about the length of surgery was complete, and found
that following imputation, the two distributions were similar (data
not shown).
The incidence rate of symptomatic VTE in LMWH group was
higher than that in Warfarin group, although the difference didn’t
reach statistical significance. We suspect that surgeons might pay
more attention to the newly-introduced LMWH and be more on
the lookout for VTE symptoms among patients treated with
LMWH. However, the same could not be said about infections,
because no link had been suspected between these two at that
time. So there may be some ascertainment bias for the VTE
outcomes, but not for infections. While we showed that LMWH
use was similar in its effectiveness to prevent symptomatic VTE as
warfarin, we observed a significant increase in surgical site
infections in patients treated with LMWH. We attribute this to
the fact that most GLORY patients from US received LMWH
within 12–24 hours of surgery (as per ACCP guidelines). Thus
anticoagulation is present immediately with a fresh postoperative
wound and while patients are undergoing early rehabilitation,
hindering the wound healing process and exposing patients to
potential infectious agents. In fact, we observed in a separate
analysis of GLORY data from Europe that timing of LMWH
prophylaxis around surgical time was associated with significantly
higher risk of infections (unpublished observation).It should be
mentioned that more than half of these surgical site infections (28
of 49) were treated without reoperation. Clearly the line between a
superficial and a deep infection is a gray line, most surgeons would
be wary of any level of infection. Furthermore, the rarity of deep
infections (0.29%) makes comparison of this outcome impossible in
this study.
We observed an increase in reoperations in the LMWH group,
but were not able to test if there was an increase in reoperations
specifically due to infection. We attribute this to a limitation in
registry data. In GLORY, the reason for reoperation was not
always clearly delineated; 29 out 76 patients had reoperations
without an attributable cause (data not shown). We acknowledge
that in a clinical scenario, a patient may have a reoperation for
Table 2. Comparison of Outcomes from the US Study Population of the Global Orthopedic Registry (GLORY).
LMWH{(N=1,561) Warfarin{ (N=2,194) Odds Ratio*(95% CI) P Value
Length of stay, median (IQR) 3 (3–5) 4 (3–4) 0.98 (0.93, 1.03) 0.40
General complications 48 (3.1) 58 (2.6) 1.41 (0.96, 2.07) 0.08
Cardiac 9 (0.6) 11 (0.5)
Medical 16 (1.0) 19 (0.9)
Surgical 25 (1.6) 31 (1.4)
Symptomatic VTE 23 (1.5) 19 (0.9) 1.72 (0.93, 3.17) 0.08
Blood transfusion 459 (29.4) 483 (22.0) 1.75 (1.51, 2.04) ,.001
Volume (ml), mean (SD) 614 (371) 524 (227) ,.001
Bleeding 97 (6.2) 45 (2.1) 3.82 (2.64, 5.52) ,.001
Bleeding Complications 13 (0.8) 6 (0.3) 2.95 (1.10, 7.89) 0.03
Surgical site infection 25 (1.6) 13 (0.6) 2.79 (1.42, 5.45) 0.003
Superficial infection 20 (1.3) 9 (0.4) 3.47 (1.53, 7.84) 0.003
Deep infection 5 (0.4) 4 (0.2)
Reoperation 38 (2.3) 28 (1.3) 1.77 (1.07, 2.93) 0.03
Due to infection 11 (0.7) 11 (0.5)
LMWH: low molecular weight heparin; IQR: inter quartile range; SD: standard deviation; CI, confidence interval; VTE: venous thromboembolism.
*LMWH vs. Warfarin.
{Values are given as the number of patients with the percentage in parentheses, unless otherwise indicated.
doi:10.1371/journal.pone.0091755.t002
Table 3. Subgroup Analysis of Compliant Use from the US Study Population of the Global Orthopedic Registry (GLORY).
LMWH{(N=973) Warfarin{(N=575) Odds Ratio*(95% CI) P Value
Bleeding 66 (6.8) 16 (2.8) 3.98 (2.10, 7.56) ,.001
Bleeding Complications 6 (0.6) 1 (0.2)
Surgical site infection* 20 (2.0) 3 (0.4) 5.07 (1.30, 19.77) 0.02
Superficial infection 17 (1.7) 2 (0.3) 5.63 (1.18, 26.99) 0.03
Deep infection 3 (0.4) 1 (0.1)
Reoperation* 29 (3.0) 6 (0.9) 3.42 (1.26, 9.29) 0.02
LMWH: low molecular weight heparin; CI, confidence interval; VTE: venous thromboembolism.
*LMWH vs. Warfarin.
{Values are given as the number of patients with the percentage in parentheses.
doi:10.1371/journal.pone.0091755.t003
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multiple causes (e.g. dislocation in conjunction with wound
drainage) and in un-adjudicated study setting, it is not always
simple to attribute the cause of a reoperation. However, from the
patient’s perspective, any reoperation is a negative outcome and
should be evaluated as we did.
Using ACCP guidelines, we found that compliance among
patients treated with warfarin was much lower than that among
patients with LMWH, presumably due to a preference by surgeons
to limit the INR to levels below those recommended by clinical
guidelines. This caused some concerns that our comparison
between LMWH and warfarin may be problematic due to low
dosage of warfarin. However, our analysis among subset of
patients with compliant use of either agent clearly demonstrated
the association with more infectious outcomes following LMWH
treatment.
Our study has several limitations that may affect its internal and
external validity. First, although this registry was designed for
identifying functional outcomes and complications following hip or
knee arthroplasty, it is mostly used for generating hypothesis, as
well as providing information about real-world practices. Second,
with prophylaxis choice not randomized, the difference we found
in the infectious outcomes may not be attributable to the exposure
we studied. Even after we used propensity score weighting to
balance the difference between treatment groups, there remain
other unknown or unobserved confounders such as hospital or
surgeon procedure volume [30] and clinic/hospital urban/
teaching status [5]. Third, due to high compliance with VTE
prophylaxis, there are few patients in naı¨ve control group from the
registry, preventing us from constructing a placebo group.
However, unadjusted analysis did show that baseline rate of
infections in naı¨ve control group was similar to that of warfarin
group but less than that of LMWH group (unpublished
observation). And finally, the sample size was enough for the
main outcomes (bleeding and infections) but not for most subgroup
analyses. The limited size of the study and voluntary nature of
surgeon participation may render the study less generalizable.
Given that there are approximately 1 million major orthopedic
procedures each year in US, doubling of the risk of infection from
less than 1% to approximately 2% may present significant burden
to the healthcare system. This investigation is consistent with the
observed increase in the infection burden in US for hip and knee
arthroplasty from 1998 to 2004 when the use of LMWH use
became increasingly prevalent [5]. However, LMWH should not
be abandoned for prophylactic use against venous thromboem-
bolism. Instead, it should be used prudently as shown in clinical
practices [31] and hospital settings [32]. The same prudence
should be exercised for any new anticoagulant, as a recent study
reported significant wound complications following administration
of direct factor-Xa inhibitor as a stronger thrombotic agent
compared to LMWH in lower limb arthroplasty [33].
In conclusion, the choice of thromboprophylaxis may be
associated with significant higher incidences of surgical site
infections and reoperations, in addition to bleeding. Postoperative
surgical site infection should be assessed routinely in future clinical
trials of new anticoagulants and registry for joint replacements, as
this may impact both risk-benefit and cost-benefit evaluations of
VTE prevention regimens following joint arthroplasty.
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